Oregon Department of Corrections
Approved Formulary
Search by name
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Hazardous Drugs
In-Cell HD
Earned In-Cell
Formulary Duration Restrictions
Therapeutic Substitutions
Webpage Links
Add Formweb to your mobile device
Android
iOS
Home
QuickStart
Admin
February P&T meeting minutes have been posted.
Oregon Department of Corrections
Approved Formulary
Search by name
Additional search options
Search by class
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Hazardous Drugs
In-Cell HD
Earned In-Cell
Formulary Duration Restrictions
Therapeutic Substitutions
Webpage Links
Search results for:
valproic acid
valproic acid
Hazardous Drugs
Handling Guide (Group 3: Reproductive Risk)
Cell Status
NFISA
Form
Strength
CAPSULE, ORAL
250 mg
SYRUP, ORAL
250 mg/5 mL
Additional Information:
FEBRUARY 2024 P&T MINUTES
Last updated:
Mar. 11, 2024
Black Box Warning:
Risk to children exposed in utero
FDA Drug Safety:
Valproate Anti-seizure Products Contraindicated for Migraine Prevention in Pregnant Women due to Decreased IQ Scores in Exposed Children
UpToDate
Micromedex
Pharmacist's Letter
FDA DailyMed Package Insert
WebMD Pill Identifier
FEBRUARY 2024 P&T MINUTES